CXCL10 is a chemokine crucial for immune cell recruitment and inflammation modulation, especially ‎within the tumor microenvironment.‎ This review critically analyzes the underexplored role of CXCL10 in modulating ‎JAK/STAT, MAPK/ERK, and PI3K/Akt pathways across different tumor types, highlighting ‎inconsistencies in current research and proposing novel therapeutic strategies based on ‎research ‎from databases such as PubMed and Scopus. The gene discussed is AKT1; the disease is neoplasm.